Drostanolone propionate

COMPOSITION:

Each ml contains: Drostanolone propionate 100 mg

PHARMACOLOGICAL ACTION:

Drostanolone propionate is an injectable anabolic preparaon. Aer injecon, methenolone enanthate is
gradually released from the intramuscular depot and subsequently hydrolyzed into nandrolone.

INDICATIONS:

Drostanolone should be used with cauon in paents with any disease, especially cancer of the prostate or
breast, liver, heart. Kidney disease, allergy, enlarged prostate. High dosage, long term use of androgens
has been related to liver cancer. This drug should not be used during pregnancy or lactaon. Females
should be monitored for signs virilizaon, such as deepening of the voice. Facial ha, acne, menstrual
irregularity or clitoral enlargement, consult the doctor promptly if any of these symptoms occur. Use in
children should not be recommended due to the possibility this drug may have undesirable effects
related to the growth of the child. It should be used with extreme cauon in geriatric men because they
are at higher risk for developing enlarged prostates or prostate cancer when using this medicaon.

CONTRA-INDICATIONS:

Not intended for use in children. Known or suspected prostac carcinoma and mammary carcinoma in
the male. Not intended for use in female paents other than those with disseminated breast cancer.
Contraindicated in nephrosis or the nephroc phase of nephris, cardiac and renal failure, hypercalcaemia,
oedema, jaundice, liver disease with impaired bilirubin excreon, tescular and hepac carcinoma.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:

Virilizaon which appears in sensive women as hoarseness, acne, hirsusm, and increased libido; in
prepubertal boys as an increased frequency of erecons and phallic enlargement, and in girls as an
increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change
which may end in a long-lasng, somemes irreversible deepening of the voice

OTHER ADVERSE REACTIONS MAY INCLUDE:

Oligospermia and decreased ejaculatory volume; Suppression of ovarian acvity, atrophy of the breasts
and endometrial ssue. Amenorrhea and inhibion of spermatogenesis. Water and salt retenon.
Premature epiphyseal closure. If signs of virilizaon develop, treatment should be disconnued. Increase in
nitrogen retenon and skeletal weight;Oedema; Increased vascularity of the skin;Increased growth of the
bone; Elderly males may become over-smulated.

INTERACTIONS:

Liver-enzyme-inducing agents may reduce the effects of Drostanolone propionate by enhancing its
metabolism in the liver.

STORAGE INSTRUCTIONS:

Store at room temperature below 30 °C. Protect From Light.